Sparsentan is a dual endothelin receptor antagonist (ETA and ETB) used to treat patients with protein-rich urine caused by primary focal segmental glomerulosclerosis or kidney disease associated with diabetes… Read more
![Chemical structure of 2'-(Methoxycarbonyl)-4'-methyl-[1,1'-biphenyl]-2-sulfonic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-Methoxycarbonyl-4-methyl-11-biphenyl-2-sulfonic-Acid.png&w=3840&q=75)
![Chemical structure of 2'-Cyano-4'-methyl-[1,1'-biphenyl]-2-sulfonic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-Cyano-4-methyl-11-biphenyl-2-sulfonic-Acid.png&w=3840&q=75)

![Chemical structure of 4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1255948-69-6-4-2-Butyl-4-oxo-13-diazaspiro4.4non-1-en-3-ylmethyl-2-ethoxymethyl-11-biphenyl-2-sulfonic-Acid.png&w=3840&q=75)
![Chemical structure of 4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1026355-73-6-4-2-Butyl-4-oxo-13-diazaspiro4.4non-1-en-3-ylmethyl-N-45-dimethylisoxazol-3-yl-2-ethoxymethyl-N-methoxymethyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)
![Chemical structure of 4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F254741-35-0-4-2-Butyl-4-oxo-13-diazaspiro4.4non-1-en-3-ylmethyl-N-45-dimethylisoxazol-3-yl-2-methoxymethyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)
![Chemical structure of 4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-formyl-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F254737-96-7-4-2-Butyl-4-oxo-13-diazaspiro4.4non-1-en-3-ylmethyl-N-45-dimethylisoxazol-3-yl-2-formyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)
![Chemical structure of 4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-2-en-1-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2567159-90-2-4-2-Butyl-4-oxo-13-diazaspiro4.4non-2-en-1-ylmethyl-N-45-dimethylisoxazol-3-yl-2-ethoxymethyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)
![Chemical structure of 4'-((2-Butyryl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-2-Butyryl-4-oxo-13-diazaspiro4.4non-1-en-3-ylmethyl-N-45-dimethylisoxazol-3-yl-2-ethoxymethyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)



![Chemical structure of Ethyl 2'-(N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)sulfamoyl)-2-(ethoxymethyl)-[1,1'-biphenyl]-4-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1247868-68-3-Ethyl-2-N-45-dimethylisoxazol-3-yl-N-methoxymethylsulfamoyl-2-ethoxymethyl-11-biphenyl-4-carboxylate.png&w=3840&q=75)
![Chemical structure of N-(4,5-Dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-4'-(hydroxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1098924-76-5-N-45-Dimethylisoxazol-3-yl-2-ethoxymethyl-4-hydroxymethyl-N-methoxymethyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)
![Chemical structure of N-(4,5-Dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-4'-((methyl(nitroso)amino)methyl)-[1,1'-biphenyl]-2-sulfonamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-45-Dimethylisoxazol-3-yl-2-ethoxymethyl-N-methoxymethyl-4-methylnitrosoaminomethyl-11-biphenyl-2-sulfonamide.png&w=3840&q=75)










Sparsentan is a dual endothelin receptor antagonist (ETA and ETB) used to treat patients with protein-rich urine caused by primary focal segmental glomerulosclerosis or kidney disease associated with diabetes or hypertension. To support rigorous pharmaceutical analysis, this category provides high-quality Sparsentan reference standards, including synthetic impurities, metabolites such as glucuronides, and stable isotope labelled compounds. These materials are essential for pharmaceutical laboratories performing impurity profiling, analytical testing, and method validation to ensure the quality and consistency of drug formulations. By using these certified reference materials, researchers can accurately identify and quantify degradants and by-products throughout the development and manufacturing process, maintaining strict adherence to quality control standards for this complex therapeutic agent.